Cord Blood Adropin as an early predictor for fetal Growth and Cardiac Complications in Infants of Diabetic Mothers

Document Type : Original Article

Authors

1 Pediatrics Department ,Faculty of Medicine, Ain Shams University, Cairo, Egypt

2 Clinical pathology, Ain Shams University,cairo, Egypt

3 Pediatrics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

10.21608/asmj.2025.364053.1406

Abstract

Background: Adropin is a polypeptide involved in energy homeostasis, insulin response, and endothelial function, significantly
impacting fetal development. Numerous studies suggest that it regulates fetal growth.
Aim of the Work: The current study sought to investigate cord blood adropin levels in infants of diabetic mothers and to
correlate them with fetal growth, and cardiac complications.
Patients and Methods: Thirty infants of mothers with diabetes mellitus (IDM) and thirty infants whose mothers did not
have diabetes were enrolled in this comparative case-control study. Adropin levels were assayed by non-competitive enzyme-
linked immunosorbent assay in the cord blood of all enrolled neonates. Birth weight and ponderal index were recorded.
Echocardiographic measurements were conducted in the first three days of life.
Results: Adropin levels were significantly lower in infants of diabetic mothers [median (IQR): 80.25 (55.5 – 99) pg/ml]
compared to infants of non-diabetic mothers [ median (IQR): 718.25 (487-944)]. Growth-related metrics (including birth
weight and ponderal index) and echocardiographic measurements of left ventricular end-systolic dimensions were negatively
correlated with adropin levels.
Conclusion: Cord blood adropin levels can be used as a foreteller of fetal growth and cardiac complications in infants of
diabetic mothers.

Keywords

Main Subjects

Files

Share

How to cite

Statistics